European Medicines Agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy
Sign Up to like & getrecommendations! Published in 2019 at "ESMO Open"
DOI: 10.1136/esmoopen-2019-000570
Abstract: On 21 November 2016, the European Commission issued a marketing authorisation valid throughout the European Union for ixazomib in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have… read more here.
Keywords: ixazomib; received least; multiple myeloma; myeloma received ... See more keywords